Why we believe Telix Pharmaceuticals is an attractive investment 

In the dynamic landscape of investing, uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts. Telix Pharmaceuticals (ASX:TLX), despite its relatively short tenure on the ASX, emerges as a beacon of promise in the realm of biotech ventures.  

In evaluating investment opportunities, the lack of an extensive historical record can obscure a company’s growth inflection points, which are critical to our decision-making process. In their absence, we rely on historical analogs from our investment experience to identify key performance indicators. Telix Pharmaceuticals, despite its brief history on the ASX, has demonstrated extraordinary progress by generating over $100 million in revenue in the March 2023 quarter, a remarkable leap from zero, less than twelve months ago. The rapid growth underscores the significant potential of their product offerings. 

As a self-described “theranostics” company, Telix focuses on developing radiopharmaceuticals for cancer diagnosis and treatment. Their leading product, Illuccix, represents a breakthrough in accurately detecting prostate cancer. The swift achievement of revenue milestones attests to the company’s adept management of the migration from Research & Development to commercialisation, including the proficient handling of the complexities of licensing, production, and global distribution. Such success significantly enhances our optimism about Telix’s growth trajectory, especially with plans to extend Illuccix’s penetration internationally and across new products. 

Anticipated growth hinges on Telix’s entry into the radio-diagnostic markets for kidney and brain cancers, which are currently untapped and represent a combined annual opportunity of approximately U.S.$1.3 billion. Additionally, a forthcoming radiotherapy treatment for prostate cancer might exceed the total market potential of all diagnostic products. 

The combination of Telix’s promising product pipeline and management’s proven execution skills portends strong future cash flow growth and substantial value increase. Furthermore, the radiopharmaceutical sector’s growing appeal to major pharmaceutical companies, as evidenced by recent acquisitions, positions Telix as a prime candidate for strategic partnerships or acquisition, amplifying its attractiveness as an investment. 

The Montgomery Fund, Montgomery [Private] Fund, Montgomery Small Companies Fund and Australian Eagle Trust Long Short Fund own shares in Telix Pharmaceuticals. This article was prepared 19 April 2024 with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade Telix Pharmaceuticals, you should seek financial advice. 


View all funds